With many such obstacles overcome, along with a handful of regulatory approvals granted, ASO- and siRNA-based therapies have received a shot in the arm. Dozens of candidates are now in clinical ...

Ben Hargreaves speaks to Liberate Bio, a company that is hoping to address the delivery issues that could prevent mRNA, as well as siRNA and ASO therapeutics, from reaching their full potential ...